Umeå University's logo

umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Blood based metabolic markers of glioma from pre-diagnosis to surgery
Umeå University, Faculty of Science and Technology, Department of Chemistry.ORCID iD: 0000-0001-9228-0625
Umeå University, Faculty of Science and Technology, Department of Chemistry.
Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.ORCID iD: 0000-0002-8258-0699
Umeå University, Faculty of Medicine, Department of Radiation Sciences, Oncology.
Show others and affiliations
2024 (English)In: Scientific Reports, E-ISSN 2045-2322, Vol. 14, article id 20680Article in journal (Refereed) Published
Abstract [en]

Gliomas are highly complex and metabolically active brain tumors associated with poor prognosis. Recent reports have found altered levels of blood metabolites during early tumor development, suggesting that tumor development could be detected several years before clinical manifestation. In this study, we performed metabolite analyses of blood samples collected from healthy controls and future glioma patients, up to eight years before glioma diagnosis, and on the day of glioma surgery. We discovered that metabolites related to early glioma development were associated with an increased energy turnover, as highlighted by elevated levels of TCA-related metabolites such as fumarate, malate, lactate and pyruvate in pre-diagnostic cases. We also found that metabolites related to glioma progression at surgery were primarily high levels of amino acids and metabolites of amino acid catabolism, with elevated levels of 11 amino acids and two branched-chain alpha-ketoacids, ketoleucine and ketoisoleucine. High amino acid turnover in glioma tumor tissue is currently utilized for PET imaging, diagnosis and delineation of tumor margins. By examining blood-based metabolic progression patterns towards disease onset, we demonstrate that this high amino acid turnover is also detectable in a simple blood sample. These findings provide additional insight of metabolic alterations during glioma development and progression.

Place, publisher, year, edition, pages
Springer Nature, 2024. Vol. 14, article id 20680
Keywords [en]
Glioma, Glioblastoma, Blood metabolites, Early detection, Surgery, Liquid biopsy
National Category
Biochemistry Molecular Biology
Identifiers
URN: urn:nbn:se:umu:diva-229233DOI: 10.1038/s41598-024-71375-6ISI: 001457725800044PubMedID: 39237693Scopus ID: 2-s2.0-85203420003OAI: oai:DiVA.org:umu-229233DiVA, id: diva2:1895468
Funder
Swedish Cancer Society, 19 0370PJSwedish Cancer Society, 22 31PJ01HSwedish Cancer Society, 21 1384Pj01HCancerforskningsfonden i Norrland, AMP 18-907Cancerforskningsfonden i Norrland, AMP 21-1045Cancerforskningsfonden i Norrland, AMP 22-1084Cancerforskningsfonden i Norrland, AMP 23-1131Lions Cancerforskningsfond i Norr, LP21-2259Swedish Research Council, 2019-01566Sjöberg Foundation, 2020-01-07-08Familjen Erling-Perssons Stiftelse, 2021 0046Available from: 2024-09-05 Created: 2024-09-05 Last updated: 2025-04-24Bibliographically approved
In thesis
1. Metabolic signatures in blood for early detection of glioma
Open this publication in new window or tab >>Metabolic signatures in blood for early detection of glioma
2024 (English)Doctoral thesis, comprehensive summary (Other academic)
Alternative title[sv]
Metaboliska signaturer i blod för tidig upptäckt av gliom
Abstract [en]

Glioma is the most common malignant primary brain tumor among adults and is often detected at a late stage of the disease. Treatment often include surgical resection of the tumor followed by combined radiochemotherapy. Yet, the prognosis given to glioma patients is often poor, with the median survival for the most common and aggressive glioma subtype glioblastoma being only 15 months. Due to limited treatment options and poor prognosis, an earlier detection of gliomas could potentially improve the outcome and quality of life for patients. Intriguingly, previous studies have shown that the glioma development may actually start several years before clinical diagnosis is given. In this thesis, a search for altered metabolite levels in blood related to glioma development was conducted, to find biomarkers that show potential to be targets in an early detection tool of glioma and to improve the understanding of the mechanism of the disease.

In Paper I, pre-diagnostic metabolite levels in blood were analyzed from glioma cases that had been collected several years before they were diagnosed together with matched controls. A panel of 20 metabolites were discovered that could predict glioma development up to 8 years before diagnosis in the discovery cohort and up to 2 years before diagnosis in the validation cohort. The altered metabolites showed indication of an altered energy metabolism and imbalanced redox homeostasis.

In Paper II, the altered metabolite levels within 8 years to glioma diagnosis related to an altered energy metabolism was replicated. Longitudinal blood metabolite analysis from years before diagnosis to the time of surgery revealed an altered amino acid metabolism. A set of metabolites with diagnostic potential at surgery and years before diagnosis was presented.

In Paper III, a discovery analysis was conducted on altered metabolite levels at the time of glioma surgery compared to years before diagnosis. A large set of metabolites was significantly altered at surgery, with several metabolic pathways altered including the amino acid metabolism. The pre-diagnostic 20-metabolite panel discovered in Paper I was revisited and their levels were analyzed at surgery, where 8 metabolites showed further significantly elevated levels at surgery as compared to years before, indicating early detection and diagnostic potential for those metabolites.

Place, publisher, year, edition, pages
Umeå: Umeå University, 2024. p. 67
Keywords
Glioma, glioblastoma, liquid biopsy, blood, metabolites, early detection, surgery, N-lactoyl-amino-acids, N-lactoyl-phenylalanine
National Category
Cancer and Oncology Analytical Chemistry Bioinformatics (Computational Biology)
Identifiers
urn:nbn:se:umu:diva-230465 (URN)9789180705011 (ISBN)9789180705028 (ISBN)
Public defence
2024-11-08, Stora hörsalen (KBE303), KBC-huset, Linnaeus väg 6, Umeå, 09:00 (English)
Opponent
Supervisors
Available from: 2024-10-11 Created: 2024-10-01 Last updated: 2024-10-02Bibliographically approved

Open Access in DiVA

fulltext(3296 kB)97 downloads
File information
File name FULLTEXT01.pdfFile size 3296 kBChecksum SHA-512
172d1325bb64a5e90b8f044af612342ffc0259ea32fe86d5811e28b41ec843f8e4e040c35590c9ed14ea787474931abd33e4aec7166f87abc2f655a64c0c8731
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Authority records

Löding, SebastianAntti, HenrikSjöberg, Rickard L.Melin, Beatrice S.Björkblom, Benny

Search in DiVA

By author/editor
Löding, SebastianAntti, HenrikSjöberg, Rickard L.Melin, Beatrice S.Björkblom, Benny
By organisation
Department of ChemistryNeurosciencesOncology
In the same journal
Scientific Reports
BiochemistryMolecular Biology

Search outside of DiVA

GoogleGoogle Scholar
Total: 97 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 415 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf